Generic drug
Lamotrigine price, strengths & recalls
Generic of Lamictal, Subvenite
Pharmacies pay $1.45 for 30 tablets of Lamotrigine 100 mg tablet this week, and from $0.81 to $53.56 across its 17 priced strengths and forms. 41 manufacturers make it. It is in shortage (being discontinued). It has 13 recalls on record, none ongoing. Its official label last changed on June 25, 2026.
Being discontinuedGeneric- Fair cash price
- $12.17
- Strengths
- 17
- Makers
- 41
- Updated
- Nov 11
Lamotrigine price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 25 mg (24 hr) extended-release tablet | $0.3615 | $10.84 / 30 tablets | ||
| 50 mg (24 hr) extended-release tablet | $0.5513 | $16.54 / 30 tablets | ||
| 100 mg (24 hr) extended-release tablet | $0.6671 | $20.01 / 30 tablets | ||
| 200 mg (24 hr) extended-release tablet | $0.6485 | $19.45 / 30 tablets | ||
| 250 mg (24 hr) extended-release tablet | $1.21 | $36.44 / 30 tablets | ||
| 300 mg (24 hr) extended-release tablet | $1.28 | $38.29 / 30 tablets | ||
| 25 mg orally disintegrating tablet | $1.28 | $38.39 / 30 tablets | ||
| 50 mg orally disintegrating tablet | $1.33 | $39.75 / 30 tablets | ||
| 100 mg orally disintegrating tablet | $1.59 | $47.69 / 30 tablets | ||
| 200 mg orally disintegrating tablet | $1.79 | $53.56 / 30 tablets | ||
| Pack | Not priced this week | |||
| Pack | $9.50 | $9.50 / 1 kit | ||
| 25 mg tablet | $0.0270 | $0.81 / 30 tablets | ||
| 100 mg tablet | $0.0483 | $1.45 / 30 tablets | ||
| 150 mg tablet | $0.0688 | $2.06 / 30 tablets | ||
| 200 mg tablet | $0.0801 | $2.40 / 30 tablets | ||
| 5 mg tablet for oral suspension | $0.1530 | $4.59 / 30 tablets | ||
| 25 mg tablet for oral suspension | $0.1503 | $4.51 / 30 tablets | ||
The lowest cost per tablet is 25 mg tablet at $0.0270. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of lamotrigine
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 13 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Lamotrigine
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.LAMOTRIGINE Tablets, for oral useInitial U.S. Approval: 1994
WARNING: SERIOUS SKIN RASHES
WARNING: SERIOUS SKIN RASHES
See full prescribing information for complete boxed warning.
Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:
coadministration with valproate.
exceeding recommended initial dose of lamotrigine.
exceeding recommended dose escalation for lamotrigine.
presence of the HLA-B*1502 allele. (5.1)
Benign rashes are also caused by lamotrigine; however, it is not possible to predict which rashes will prove to be serious or life threatening. Lamotrigine should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)
Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking lamotrigine as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by lamotrigine include (1) coadministration of lamotrigine with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine, (3) exceeding the recommended dose escalation for lamotrigine, or (4) the presence of the HLA-B*1502 allele However, cases have occurred in the absence of these factors.
Nearly all cases of life-threatening rashes caused by lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.
Although benign rashes are also caused by lamotrigine, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, lamotrigine should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring [see Warnings and Precautions (5.1)].
Recent major changes (as listed on the label)
Boxed Warning
| 10/2025
|
Dosage and Administration (2.1, 2.2, 2.4)
| 4/2025
|
Warnings and Precautions,
Serious Skin Rashes
| 10/2025
|
Concomitant Use with Estrogen-Containing Products, Including Oral
Contraceptives (5.9)
| 4/2025
|
Sudden Unexplained Death in Epilepsy (5.12) - removal
| 4/2025
|
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA022115 · Glaxosmithkline LLC
- First approved
- May 29, 2009 (17 years ago)
- Latest approved change
- October 10, 2025
- Approved label
- PDF, Oct 14, 2025
- Generic makers
- 27 approved generic applications on the market
- Last patent listed
- January 7, 2029
Lamotrigine questions
How much does lamotrigine cost without insurance?
Pharmacies pay about $1.45 for 30 tablets of lamotrigine 100 mg tablet ($0.0483 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $12.17. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of lamotrigine?
Is lamotrigine in shortage?
Yes. 6 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has lamotrigine been recalled?
13 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the lamotrigine label last change?
The official label was last updated on June 25, 2026 (version 25). See what changed.
Talk about lamotrigine
No comments yet. Questions, tips, what worked for you - start the conversation.